Monthly Archives: October 2009

Industrial and Environmental Biotech in the Blogosphere

This week we start off with a United Nations report that urges caution on biofuels. Green Inc, a New York Times blog writes, “The study concluded that whether a biofuel is climate-friendly or not depends largely on whether it is based on crops or production residues. Biofuels of the latter category were generally considered beneficial for the environment, and generating electricity locally from waste materials was found — in most cases — to be more Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , ,

Compounded Climate Accounting Errors

Timothy Searchinger, visiting scholar at Princeton University, Dan Kammen of the University of California Berkeley, David Tilman of the University of Minnesota and other authors from the Environmental Defense Fund published an interesting new proposal in the Policy Forum section of Science magazine today. The argument put forward is that “Replacing fossil fuels with bioenergy does not by itself reduce carbon emissions, because the CO2 released by tailpipes and smokestacks is roughly the same per Read More >

Biofuels & Climate Change  |  1 Comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

Development continues for osteoporosis drug

Osteologix, Inc. (OLGX.OB) will continue the clinical development for its osteoporosis drug, NB S101 (strontium malonate), in the U.S. and worldwide. Additionally, the company wants to recognize World Osteoporosis Day’s significance and make more people aware of its research dedicated to improving the lives of people with osteoporosis. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Oncolytics invests in private biotech company

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) invested in British Canadian Biosciences Corp., a privately held biotechnology company specializing in the development of peptides for the treatment of a variety of conditions, including cancer. Oncolytics has purchased all of the convertible preferred shares of BCBC in exchange for 200,000 common shares of Oncolytics. If converted to common shares, Oncolytics would own 10% of the outstanding BCBC common shares. In addition, Oncolytics has obtained a right, Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Podcast with Fast Forward’s Tim Coetzee

Biotech Now’s Tracy Krughoff spoke with Dr. Tim Coetzee, president of Fast Forward, a subsidiary of the National Multiple Sclerosis Society. Fast Forward will be one of the advocacy organizations presenting at the Eighth Annual BIO Investor Forum. Listen now!

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,